

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Are Bogsnes

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: November 20, 2003

Examiner: To be assigned

For: Novel Process For The Separation Of Proteins Using a Ca++ Containing Eluant

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/290,856 filed on April 13, 1999 and continuation application USSN 09/633,526.

The references are as follows:


1. U.S. Patent 5,633,350
2. U.S. Patent 3,649,456
3. U.S. Patent 6,214,547
4. U.S. 2002/0160955A1
5. EP 0195691
6. Konrad, Annals of the New York Academy of Sciences (1983) 413:12-22

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: November 20, 2003

Respectfully submitted,

 FOR Reza Green

Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Len S. Smith, Reg. No. 43,139

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 5432.220-US

Serial No. To be assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant: Are Bogness

(Use several sheets if necessary)

Filing Date November 20, 2003?

Group to be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		3,649,456	03/14/72	Benneville et al.	195	66	
		5,633,350	05/27/97	Fischer et al.	530	381	
		6,214,547	04/2001	Kjeldsen et al.	435	6	
		2002/0160955A 1	10/2001	Dubaquic et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		EP 0195691	09/1986	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Konrad, Annals of the New York Academy of Sciences (1983) 413:12-22

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.